Anne L. Fuhlbrigge, MD, MS, Seung Jin Bae, MS, MPharm, Scott T

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

What drives prescription patterns in pediatric asthma management?

Allergen immunotherapy: A practice parameter third update

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Fatty acids, inflammation, and asthma

A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma L. Keoki Williams, MD, MPH,

Jessica P. Hollenbach, PhD, Michelle M. Cloutier, MD

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

David A. Khan, MD Journal of Allergy and Clinical Immunology

Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study John M. Brehm, MD, MPH, Brooke Schuemann, BS,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence L. Keoki Williams, MD, MPH, Edward L. Peterson,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

Physician needs in health informatics: Just ask the docs

Peter M. Wolfgram, MD, David B. Allen, MD

Etiology of asthma exacerbations

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study Katrina Abuabara, MD, MA, Ole Hoffstad, MS,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Phillip Lieberman, MD, David Golden, MD

Ovalbumin content of influenza vaccines

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Effect of ingested H1 antihistamines on methacholine challenge

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Personalized asthma therapy in blacks—the role of genetic ancestry

Autophagy: Nobel Prize 2016 and allergy and asthma research

Higher incidence of pediatric anaphylaxis in northern areas of the United States William J. Sheehan, MD, Dionne Graham, PhD, Lin Ma, MS, Sachin Baxi,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Corinne A. Keet, MD, MS, Wayne G. Shreffler, MD, PhD, Roger D

Prevention of food allergy: Beyond peanut

One step forward, 2 steps back: The enigma of preschool wheeze

The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study Tetyana.

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Reply Journal of Allergy and Clinical Immunology

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Measles and immunomodulation

Neil E. Alexis, PhD, John C. Lay, PhD, Martha Almond, RRT, David B

Consumer attitudes and risks associated with packaged foods having advisory labeling regarding the presence of peanuts Susan L. Hefle, PhD, Terence J.

Macrolide antibiotics and asthma treatment

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Safety and efficacy of repeated monthly carboplatin desensitization

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Modeling asthma exacerbations through lung function in children

Presentation transcript:

Cost-effectiveness of inhaled steroids in asthma: Impact of effect on bone mineral density Anne L. Fuhlbrigge, MD, MS, Seung Jin Bae, MS, MPharm, Scott T. Weiss, MD, MS, Karen M. Kuntz, ScD, A. David Paltiel, PhD Journal of Allergy and Clinical Immunology Volume 117, Issue 2, Pages 359-366 (February 2006) DOI: 10.1016/j.jaci.2005.10.036 Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Cost components as a function of time. A, Actual costs (2003 US dollars) divided into cost components (fracture-related costs, chronic asthma-related costs [excluding drugs], acute event costs, and drug costs). B, Cost as a percentage of total costs. Example: for a lifetime horizon and no ICS, fracture-related costs were 42% of total costs, compared with 32% with ICS therapy. Journal of Allergy and Clinical Immunology 2006 117, 359-366DOI: (10.1016/j.jaci.2005.10.036) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Incremental cost-effectiveness. The results of a series of 1-way sensitivity analyses are summarized in a tornado diagram. Each horizontal bar represents a given model parameter. The vertical axis sits at the base-case (400 μg/d, weighted average of effect of ICS on BMD for a lifetime time horizon) incremental cost-effectiveness estimate ($42,000/QALY). The length and position of a given horizontal bar denote the range of cost-effectiveness outcomes produced by varying that specific parameter over its plausible range. Journal of Allergy and Clinical Immunology 2006 117, 359-366DOI: (10.1016/j.jaci.2005.10.036) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions